Vaxart, Inc. Files 8-K with Regulatory Updates
Ticker: VXRT · Form: 8-K · Filed: Jun 18, 2024 · CIK: 72444
| Field | Detail |
|---|---|
| Company | Vaxart, Inc. (VXRT) |
| Form Type | 8-K |
| Filed Date | Jun 18, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, sec-filing
Related Tickers: VXRT
TL;DR
Vaxart filed an 8-K, likely with important updates for investors.
AI Summary
Vaxart, Inc. filed an 8-K on June 18, 2024, reporting an event on June 17, 2024. The filing is primarily a Regulation FD Disclosure and includes Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided text snippet.
Why It Matters
This 8-K filing indicates Vaxart, Inc. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: medium — 8-K filings can contain material information, but the specific details of this filing were not fully provided, necessitating a medium risk assessment.
Key Players & Entities
- Vaxart, Inc. (company) — Registrant
- June 17, 2024 (date) — Earliest event date
- June 18, 2024 (date) — Filing date
- Regulation FD Disclosure (disclosure_type) — Item Information
- Financial Statements and Exhibits (document_type) — Item Information
FAQ
What specific event occurred on June 17, 2024, that necessitated this 8-K filing?
The provided text snippet does not specify the exact event that occurred on June 17, 2024, only that it is the earliest reported event date for this 8-K filing.
What type of information is included in the 'Financial Statements and Exhibits' section?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific contents are not detailed in the provided text.
What is the significance of a 'Regulation FD Disclosure'?
A Regulation FD Disclosure is filed to ensure that material non-public information is disclosed to the public in a broad and non-exclusionary manner.
What is Vaxart, Inc.'s primary business according to the filing?
Vaxart, Inc. is classified under the Standard Industrial Classification code 2836 for Biological Products (no diagnostic substances).
What was Vaxart, Inc.'s former company name prior to 2016?
Prior to April 13, 2016, Vaxart, Inc. was formerly known as Aviragen Therapeutics, Inc.
Filing Stats: 489 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-06-17 17:52:37
Key Financial Figures
- $0.0001 — nge on which registered Common Stock , $0.0001 par value VXRT The Nasdaq Capital M
Filing Documents
- vxrt20240617_8k.htm (8-K) — 28KB
- ex_689659.htm (EX-99.1) — 18KB
- 0001437749-24-020543.txt ( ) — 181KB
- vxrt-20240617.xsd (EX-101.SCH) — 3KB
- vxrt-20240617_def.xml (EX-101.DEF) — 11KB
- vxrt-20240617_lab.xml (EX-101.LAB) — 15KB
- vxrt-20240617_pre.xml (EX-101.PRE) — 11KB
- vxrt20240617_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. On June 17, 2024, Vaxart, Inc. (the "Company") issued a press release providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 99.1 Press Release, dated June 17, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VAXART, INC. Dated: June 17, 2024 By: /s/ Steven Lo Steven Lo President and Chief Executive Officer